title: Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer.
abstract: Twenty-five patients with Stage III ovarian cancer were entered into a trial with intraperitoneal combinations of carboplatin (400 mg/cqm) and recombinant interferon alfa (50 MU). All patients had received prior intravenous platinum-based chemotherapy and underwent 2nd look laparotomy at study entry. Our study indicates that this combination chemotherapy is safely administered by the intraperitoneal route. Myelotoxicity was frequent, but rarely of grade 3. No major local toxicity was recorded by accessing the peritoneal cavity with a temporary catheter. The response to treatment was promising in the group of patients with less then 2 cm residual disease at study entry (15 patients); in this group, all patients had no clinical evidence of disease at the completion of the therapy. In 2 cases reexploration was performed and pCR was recorded. Only one patient of this group relapsed during a mean follow-up of 21 months. Two pCRS were also recorded in the group of patients with more than 2 cm at 2nd look (9 patients), although relapse occurred after 9 and 15 months respectively. In the remaining patients of this group, persistence of disease was observed after intraperitoneal chemotherapy.
authors.affiliation: Divisione di Oncologia Medica B., Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G. Pascale, Napoli.
authors.forename: E
authors.initials: E
authors.lastname: Ferrari
authors.forename: D A
authors.initials: DA
authors.lastname: Maffeo
authors.forename: R
authors.initials: R
authors.lastname: Graziano
authors.forename: M S
authors.initials: MS
authors.lastname: Gallo
authors.forename: S
authors.initials: S
authors.lastname: Pignata
authors.forename: L
authors.initials: L
authors.lastname: De Rosa
authors.forename: M
authors.initials: M
authors.lastname: Montella
authors.forename: M
authors.initials: M
authors.lastname: Pergola
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D016019:Survival Analysis
chemical_list: D016898:Interferon-alpha; D016190:Carboplatin